Valtrex Dosing for Genital Herpes
For immunocompetent adults with genital herpes, use valacyclovir 1 gram twice daily for 10 days for initial episodes, 500 mg twice daily for 3 days for recurrent episodes, and 500-1000 mg once daily for suppressive therapy, with dose adjustments required for renal impairment. 1
Initial Episode (Primary Infection)
Valacyclovir 1 gram orally twice daily for 10 days is the FDA-approved regimen 1. This dosing provides equivalent efficacy to acyclovir 200 mg five times daily but with superior convenience 2. Treatment should continue until clinical resolution is attained. The improved bioavailability of valacyclovir (3-5 times that of acyclovir) allows for less frequent dosing while maintaining therapeutic acyclovir levels 2.
Recurrent Episodes
Valacyclovir 500 mg twice daily for 3 days is the optimal episodic treatment regimen 1, 3. This 3-day course is equivalent in efficacy to the 5-day course for all key endpoints including lesion healing time (median 4.4 vs 4.7 days), pain duration, and episode length 3. The shorter duration improves compliance without sacrificing clinical outcomes.
- Treatment should be initiated at the first sign of prodrome or within 1 day of lesion onset for maximum benefit 4
- Patients should be provided with medication or a prescription to enable immediate self-initiation of therapy 4
- Approximately 25-26% of patients experience aborted lesions (not progressing beyond macule/papule stage) with early treatment 5, 3
Suppressive Therapy
Standard Suppressive Dosing
For patients with ≥6 recurrences per year:
- Valacyclovir 1 gram once daily is the primary recommendation 1
- Alternative: Valacyclovir 500 mg once daily for patients with <10 recurrences per year 1, 6
Critical caveat: Valacyclovir 500 mg once daily is less effective in patients with ≥10 recurrences per year and should be avoided in this population 4. These high-frequency recurrence patients require the 1 gram daily dose 6.
Efficacy and Duration
Suppressive therapy reduces recurrence frequency by ≥75% 4. In clinical trials, 65-69% of patients remained completely recurrence-free during one year of suppressive therapy 7. The recurrence-free rate remains stable across all four quarters of treatment (81-91%) 7.
- Safety and efficacy documented for up to 6 years with acyclovir, but only 1 year for valacyclovir at the time of 1998 guidelines 4
- After 1 year of continuous therapy, reassess the need for continuation as recurrence frequency naturally decreases over time 4
- Suppressive therapy reduces but does not eliminate asymptomatic viral shedding 4
Transmission Reduction
Valacyclovir 500 mg once daily is specifically indicated for reducing transmission to uninfected partners 1. This regimen significantly reduces viral shedding (78% reduction in both total and subclinical shedding) 8, though the exact magnitude of transmission prevention remains incompletely quantified 4.
HIV-Infected Patients
Valacyclovir 500 mg twice daily for suppressive therapy in HIV-infected patients 1. This population requires more aggressive dosing due to prolonged episodes and more severe disease 4.
Renal Impairment Adjustments
Dose adjustments are mandatory for patients with creatinine clearance <50 mL/min to prevent acute renal failure 1:
Recurrent Episodes (500 mg BID standard dose):
- CrCl 30-49 mL/min: No reduction needed
- CrCl 10-29 mL/min: 500 mg every 24 hours
- CrCl <10 mL/min: 500 mg every 24 hours
Suppressive Therapy (1 gram daily standard dose):
- CrCl 30-49 mL/min: No reduction needed
- CrCl 10-29 mL/min: 500 mg every 24 hours
- CrCl <10 mL/min: 500 mg every 24 hours
Suppressive Therapy (500 mg daily alternate dose):
- CrCl 30-49 mL/min: No reduction needed
- CrCl 10-29 mL/min: 500 mg every 48 hours
- CrCl <10 mL/min: 500 mg every 48 hours
Hemodialysis:
Administer the recommended dose after hemodialysis 1. Approximately one-third of acyclovir is removed during a 4-hour session.
Peritoneal Dialysis:
No supplemental dosing required after CAPD or CAVHD 1.
Important Clinical Considerations
Elderly patients are at increased risk for acute renal failure even with normal baseline renal function 1. Always assess renal function before prescribing and adjust doses accordingly.
Common pitfall: Prescribing valacyclovir 500 mg once daily for suppression in patients with ≥10 recurrences per year—this dose is inadequate for this population 4.
Resistance concerns: Acyclovir-resistant strains have been isolated during suppressive therapy but have not been associated with treatment failure in immunocompetent patients 4. Resistance is primarily a concern in immunocompromised populations.